Clinical Trials on Mets in China
Total 8 results
-
Fujian Cosunter Pharmaceutical Co. LtdUnknownSolid Tumor | C-Met Mutation-Related TumorsChina
-
Guangdong Provincial People's HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingNon-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 MutationChina
-
Sun Yat-sen UniversityNot yet recruitingNSCLC | BRAF V600 Mutation | MET Exon 14 MutationChina
-
Haihe Biopharma Co., Ltd.UnknownNegative T790M Mutation and Met AmplificationChina
-
Novartis PharmaceuticalsTerminatedAdvanced Hepatocellular Carcinoma With c-MET DysregulationChina, Hong Kong, Thailand, Singapore
-
Haihe Biopharma Co., Ltd.RecruitingC-Met Exon 14 MutationChina, Japan, United States
-
RenJi HospitalPeking University First Hospital; Shanghai Zhongshan Hospital; First Affiliated... and other collaboratorsRecruitingKidney Cancer | Renal Cell Carcinoma | ALK Gene Mutation | MET Gene Mutation | HLRCC | Renal Tumor Histology | Cutaneous Leiomyoma | BAP1 Tumor Predisposition Syndrome | VHL Syndrome | Birt-Hogg-Dube Syndrome | Familial Renal Cancer | FLCN Gene Mutation | FH Gene Mutation | Cutaneous Leiomyomata With Uterine LeiomyomataChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IVSpain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland